Utility of Cardiac Troponins in Patients with Chronic Kidney Disease

• Published in: Cardiology in review
• Main Authors: Hti Lar Seng, Nang San, Zeratsion, Gebremichael, Pena, Oscar, Tufail, Muhammad Umer, Jim, Belinda
• Format: Journal Article
• Language: English
• Published: United States 01.01.2024
• ISSN: 1538-4683
• DOI: 10.1097/CRD.0000000000000461

Cardiovascular disease is a major cause of death worldwide especially in patients with chronic kidney disease (CKD). Troponin T and troponin I are cardiac biomarkers used not only to diagnose acute myocardial infarction (AMI) but also to prognosticate cardiovascular and all-cause mortality. The diagnosis of AMI in the CKD population is challenging because of their elevated troponins at baseline. The development of high-sensitivity cardiac troponins (hs-cTns) shortens the time needed to rule in and rule out AMI in patients with normal renal function. While the sensitivity of hs-cTns is preserved in the CKD population, the specificity of these tests is compromised. Hence, diagnosing AMI in CKD remains problematic even with the introduction of high-sensitivity assays. The prognostic significance of troponins did not differ whether it is detected with standard or high-sensitivity assays. The elevation of both troponin T and troponin I in CKD patients remains strongly correlated with adverse cardiovascular and all-cause mortality, and the prognosis becomes poorer with advanced CKD stages. Interestingly, the degree of troponin elevation appears to be predictive of the rate of renal decline via unclear mechanisms though activation of the renin-angiotensin and other hormonal/oxidative stress systems remain suspect. In this review, we present the latest evidence of the use of cardiac troponins in both the diagnosis of AMI and the prognosis of cardiovascular and all-cause mortality. We also suggest strategies to improve on the diagnostic capability of these troponins in the CKD/end-stage kidney disease population.